Fig. 6

RT plus YM101 reshapes the tumor immune landscape in the 4T1 model. (a) Heatmap visualization of differentially expressed genes (DEGs) across different treatment groups. DEGs were identified using the following criteria:|log2 fold change| ≥ 1.5 and adjusted P-value < 0.05. Gene lists and statistical information are provided in Additional file 1: Table S2. (b-c) GO enrichment analysis between RT plus YM101 and monotherapy groups (RT + YM101 Vs. YM101 and RT + YM101 Vs. RT, respectively). Immune-related GO enrichment results are detailed in Additional file 1: Table S3. (d-g) Analysis of immune signature enrichment using ROAST algorithm. The heatmaps depicted the normalized expression level of genes sets. The plots show the distribution of ROAST enrichment scores for gene sets across different experimental groups. For each signature, scores were calculated using the ROAST mean statistic with genes listed in Additional file 1: Table S4. *P < 0.05; ** P < 0.01